Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki

研究成果: Comment/debate査読

抄録

The article The efficacy and safety profile of 2‑weekly dosing of bevacizumab‑containing chemotherapy for platinum‑resistant recurrent ovarian cancer, written by Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi and Daisuke Aoki was originally published Online First without Open Access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on August 30, 2021 to

本文言語English
ページ(範囲)2130
ページ数1
ジャーナルInternational Journal of Clinical Oncology
26
11
DOI
出版ステータスPublished - 2021 11

ASJC Scopus subject areas

  • 外科
  • 血液学
  • 腫瘍学

フィンガープリント

「Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル